Peripheral Nerve Society (PNS)

CRISPR Gene Editing for Transthyretin Amyloidosis Safe, Effective

June 27th 2021

Interim data from a phase 1 study from Intellia Therapeutics and Regeneron Pharmaceuticals is the first to support in vivo CRISPR genome editing in humans.

Peripheral Nerve Society (PNS)

CRISPR Gene Editing for Transthyretin Amyloidosis Safe, Effective

Trending on CGTlive®

First Patient Treated in Capsida Biotherapeutics’ Trial for Encephalopathy Gene Therapy CAP-002 Passes Away

CGTLive®’s Weekly Rewind – September 12, 2025